EU Allows Pharma To Temporarily Prioritize Reporting For COVID-19 Adverse Events

Prioritization Allowed Until The Pandemic Is Resolved

SideEffects
EU Has Extended COVID-19 Regulatory Flexibilities To Safety Reporting • Source: Shutterstock

More from Drug Safety

More from Pink Sheet